Systemic lupus erythematosus: Safe and effective management in primary care

Primary Care - Clinics in Office Practice

Volumn 37, Issue 4, 2010, Pages 767-778

  Michalski, Joseph P ^a   Kodner, Charles ^b  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Corticosteroids; Diagnosis; Hydroxychloroquine; Primary care evaluation; Primary care management; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PREDNISONE;

AGE DISTRIBUTION; ANEMIA; ANTIBODY DETECTION; ARTHRALGIA; AUTONOMIC NEUROPATHY; BLOOD CELL COUNT; BLURRED VISION; CARDIOTOXICITY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DOCTOR PATIENT RELATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; JOINT SWELLING; LEUKOPENIA; LIVER TOXICITY; NAUSEA; PEPTIC ULCER; PNEUMONIA; PREGNANCY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RACE DIFFERENCE; RAYNAUD PHENOMENON; RECOMMENDED DRUG DOSE; RETICULOCYTE COUNT; RETINOPATHY; REVIEW; SEX DIFFERENCE; STOMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THORAX PAIN; URINALYSIS; VOMITING; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIRHEUMATIC AGENTS; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHYSICIANS, PRIMARY CARE; PREDNISONE; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 78049489990     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2010.07.006     Document Type: Review

References (42)

1. McCarty D.J., Manzi S., Medsger T.A., et al. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 1995, 38(9):1260-1270.
2. Hersh A.O., von Scheven E., Jinoos Yazdany J., et al. Systemic lupus erythematosus differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009, 61(1):13-20.
3. Helmick C.G., Felson D.T., Lawrence R.C., et al. Estimates of the prevalence of arthritis and other rheumatic diseases in the United States. Arthritis Rheum 2008, 58(1):15-25.
4. Lam G.K., Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005, 23(5 Suppl 39):S120-S132.
5. Heinlen L.D., McClain M.T., Merrill J., et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007, 56(7):2344-2351.
6. Nossent J., Kiss E., Rozman B., et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010, 19:949-956.
7. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(11):1271-1277.
8. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
9. Cervera R., Khamashta M.A., Font J. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993, 72(2):113-124.
10. Mosca M., Baldini C., Bombardieri S. Undifferentiated connective tissue diseases in 2004. Clin Exp Rheumatol 2004, 22(3 Suppl 33):S14-S18.
11. Tan E.M., Feltcamp T.E., Smolen J.S., et al. Range of antinuclear antibodies in " healthy" individuals. Arthritis Rheum 1997, 40(9):1601-1611.
12. Dahle C., Skogh T., Aberg A.K. Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J Autoimmun 2004, 22(3):241-248.
13. Bernardini S., Infantino M., Bellincampi L., et al. Screening of antinuclear antibodies: comparison between enzyme immunoassay based on nuclear homogenates, purified or recombinant antigens and immunofluorescence assay. Clin Chem Lab Med 2004, 42:1155-1160.
14. Uribe A.G., Alarcon G.S., Sanchez M.L. Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits. Arthritis Rheum 2004, 51(2):258-263.
15. Kumar K., Chambers S., Gorden C. Challenges of ethnicity in SLE. Best Pract Res Clin Rheumatol 2009, 23(4):549-561.
16. Demas K.L., Costenbader K.H. Disparities in lupus care and outcomes. Curr Opin Rheumatol 2009, 21(2):102-109.
17. Fessler B.J., Alarcon G.S., McGuin G., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005, 52(5):1473-1480.
18. Alarcon G.S., McGuin G., Bertolli A.M., et al. Effect of hydroxychloroquine on survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic U S cohort (LUMINAL). Ann Rheum Dis 2007, 66(9):1168-1172.
19. Ruiz-Irasforsa G., Ramos-Casals M., Brito-Zeron P., et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus. Ann Rheum Dis 2010, 69(1):20-28.
20. Semmer A.E., Lee M.S., Harrison A.R., et al. Hydroxychloroquine retinopathy screening. Br J Ophthalmol 2008, 92(12):1653-1655.
21. Marmor M.F., Carr R.E., Easterbrook M., et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002, 109(7):1377-1382.
22. Horizon A.A., Wallace D.J. Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf 2004, 3(4):273-278.
23. Farkouh M.E., Greenberg B.P. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009, 103(9):1227-1237.
24. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365(9458):475-481.
25. Farkouh M.E., Greenberg B.P., Braden G.L., et al. Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol Dial Transplant 2004, 19(5):1149-1153.
26. Petri M. Monitoring systemic lupus erythematosus in standard clinical care. Best Pract Res Clin Rheumatol 2007, 21(4):687-697.
27. Gladman D.D., Hussain F., Ibañez D., et al. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002, 11(4):234-239.
28. Toloza S.M., Roseman J.M., Alarcón G.S., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004, 50(10):3177-3186.
29. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001, 44(7):1496-1503.
30. Tseng C.E., Buyon J.P., Kim M., et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54(11):3623-3632.
31. Bootsma H., Spronk P., Derksen R. Prevention of relapses in systemic lupus erythematosus. Lancet 1995, 345(8965):1595-1599.
32. Fortin P.R., Abrahamowicz M., Ferland D., et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008, 59(12):1796-1804.
33. Remer C.F., Weisman M.H., Wallace D.J. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001, 10(7):480-483.
34. Abu-Shakra M., Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001, 10:152-153.
35. Ortega L.M., Schultz D.R., Lenz O., et al. Review: lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010, 19(5):557-574.
36. Lima F., Buchanan N.M., Khamashta M.A., et al. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum 1995, 3:184-192.
37. Clowse M.E., Magder L., Witter F., et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006, 54(11):3640-3647.
38. Ruiz-Irastorza G., Khamashta M.A. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol 2009, 3(4):575-582.
39. Buyon J.P., Rupel A., Clancy R.M. Neonatal lupus syndromes. Lupus 2004, 13(9):705-712.
40. Lee L.A. The clinical spectrum of neonatal lupus. Arch Dermatol Res 2009, 301(1):107-110.
41. Luzzana C., Gerosa M., Riboldi P., et al. Up-date on the antiphospholipid syndrome. J Nephrol 2002, 15(4):342-348.
42. Lim W., Crowther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006, 295(9):1050-1057.